IDDI announces the appointment of Dr. Everardo Saad as Senior Medical Expert as of July 2014. Everardo brings over 12 years of experience in Medical Oncology with a special interest in clinical trial designs for stratified oncology and biomarker-based endpoints for a more efficient development of novel therapies for cancer patients.
”With the unprecedented number of new compounds that enter clinical testing, it is increasingly challenging to design trials that optimize the chance of success by making use of biomarkers, clinically useful genomic signatures, surrogate endpoints, adaptive designs, and all such like” said Dr. Saad. Damien Tremolet, IDDI’s CEO, added: “Dr Saad’s appointment is a great milestone and asset for IDDI and will certainly reinforce IDDI’s prominent role in helping pharmaceutical and biotechnology companies, as well as clinical cooperative groups and contract research organizations, optimize their drug development strategies”